Table 1.
Effects of treatment with AS601245 on the response latency time in a passive avoidance task, after cerebral ischaemia
| Groups | Latency time (s), day 8 after ischaemia | Latency time (s), day 9 after ischaemia | Latency time (s), day 10 after ischaemia |
|---|---|---|---|
| Sham-operated | 180±0 | 169±7 | 160±15 |
| Vehicle-treated ischaemic | 139±20a | 90±23a | 68±23a |
| AS601245 (40 mg kg−1)-treated ischaemic | 132±20a | 82±21a | 83±23a |
| AS601245 (60 mg kg−1)-treated ischaemic | 140±19a | 114±21a,b | 90±23a |
| AS601245 (80 mg kg−1)-treated ischaemic | 173±6c | 151±1c | 136±17c |
The compound or vehicle was given intraperitoneally 15 min and 24 h after the restoration of carotid blood flow, following 5 min global cerebral ischaemia. Data are means±s.e.m. (n=10 animals).
a
P<0.01 versus the sham-operated group.
b
P<0.05 versus vehicle-treated ischaemic group.
c
P<0.01 versus vehicle-treated ischaemic group.